Search

Your search keyword '"van Biezen, Anja"' showing total 341 results
Start Over Author "van Biezen, Anja" Search Limiters Available in Library Collection
341 results on '"van Biezen, Anja"'

3. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Author

Garderet, Laurent, Ziagkos, Dimitris, van Biezen, Anja, Iacobelli, Simona, Finke, Jürgen, Maertens, Johan, Volin, Liisa, Ljungman, Per, Chevallier, Patrice, Passweg, Jakob, Schaap, Nicolaas, Beelen, Dietrich, Nagler, Arnon, Blaise, Didier, Poiré, Xavier, Yakoub-Agha, Ibrahim, Lenhoff, Stig, Craddock, Charles, Schots, Rik, Rambaldi, Alessandro, Sanz, Jaime, Jindra, Pavel, Mufti, Ghulam J., Robin, Marie, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

4. Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

Author

Ruggeri, Loredana, Eikema, Dirk-Jan, Bondanza, Attilio, Noviello, Maddalena, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Ciardelli, Sara, Bader, Peter, Koc, Yener, Locatelli, Franco, Veelken, Joan H., Gruhn, Bernd, Evans, Pamela, Chabannon, Christian, Toubert, Antoine, and Velardi, Andrea

Published
2022
Full Text
View/download PDF

6. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Author

Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Jürgen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yáñez, Lucrecia, Beguin, Yves, Sill, Heinz, Scheid, Christof, Stelljes, Matthias, Ganser, Arnold, Zachée, Pierre, Selleslag, Dominik, de Witte, Theo, Robin, Marie, and Kröger, Nicolaus

Published
2017
Full Text
View/download PDF

7. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research

Author

Potter, Victoria T., Iacobelli, Simona, van Biezen, Anja, Maertens, Johann, Bourhis, Jean-Henri, Passweg, Jakob R., Yakhoub-Agha, Ibrahim, Tabrizi, Reza, Bay, Jacques-Olivier, Chevallier, Patrice, Chalandon, Yves, Huynh, Anne, Cahn, Jean Yves, Ljungman, Per, Craddock, Charles, Lenhoff, Stig, Russell, N.H., Fegueux, Nathalie, Socié, Gerard, Bruno, Benedetto, Meijer, Ellen, Mufti, G.J., de Witte, Theo, Robin, Marie, and Kröger, Nicolaus

Published
2016
Full Text
View/download PDF

8. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation

Author

Fioredda, Francesca, Iacobelli, Simona, van Biezen, Anja, Gaspar, Bobby, Ancliff, Phil, Donadieu, Jean, Aljurf, Mahmoud, Peters, Christina, Calvillo, Michaela, Matthes-Martin, Susanne, Morreale, Giuseppe, van 't Veer-Tazelaar, Nelleke, de Wreede, Liesbeth, Al Seraihy, Amal, Yesilipek, Akif, Fischer, Alain, Bierings, Marc, Ozturk, Gulyuz, Smith, Owen, Veys, Paul, Ljungman, Per, Peffault de Latour, Régis, Sánchez de Toledo Codina, José, Or, Reuven, Ganser, Arnold, Afanasyev, Boris, Wynn, Robert, Kalwak, Krzysztof, Marsh, Judith, and Dufour, Carlo

Published
2015
Full Text
View/download PDF

9. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

Author

Radujkovic, Aleksandar, Guglielmi, Cesare, Bergantini, Stefania, Iacobelli, Simona, van Biezen, Anja, Milojkovic, Dragana, Gratwohl, Alois, Schattenberg, Antonius V.M.B., Verdonck, Leo F., Niederwieser, Dietger W., de Witte, Theo, Kröger, Nicolaus, and Olavarria, Eduardo

Published
2015
Full Text
View/download PDF

10. Efficacy and Outcome of Allogeneic Transplantation in IgD and Nonsecretory Myeloma. A Report on Behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Author

Morris, Curly, Iacobelli, Simona, Gahrton, Gösta, van Biezen, Anja, Drake, Mary, Garderet, Laurent, Potter, Michael, Schattenberg, Anton V., Cornelissen, Jan J., Hamladji, Rose-Marie, Martelli, Massimo, Petersen, Eefke, Rovira, Montserrat, Bandini, Giuseppe, Kroger, Nicolaus, and de Witte, Theo

Published
2015
Full Text
View/download PDF

11. Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party

Author

Robin, Marie, Ruggeri, Annalisa, Labopin, Myriam, Niederwieser, Dietger, Tabrizi, Reza, Sanz, Guillermo, Bourhis, Jean-Henri, van Biezen, Anja, Koenecke, Christian, Blaise, Didier, Tischer, Johanna, Craddock, Charles, Maillard, Natacha, Mohty, Mohamad, Russel, Nigel, Schetelig, Johannes, Finke, Jürgen, Gluckman, Eliane, de Witte, Theo M., Rocha, Vanderson, and Kroger, Nicolaus

Published
2015
Full Text
View/download PDF

12. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Author

Waszczuk-Gajda, Anna, primary, Penack, Olaf, additional, Sbianchi, Giulia, additional, Koster, Linda, additional, Blaise, Didier, additional, Reményi, Péter, additional, Russell, Nigel, additional, Ljungman, Per, additional, Trneny, Marek, additional, Mayer, Jiri, additional, Iacobelli, Simona, additional, Kobbe, Guido, additional, Scheid, Christof, additional, Apperley, Jane, additional, Touzeau, Cyrille, additional, Lenhoff, Stig, additional, Jantunen, Esa, additional, Anagnostopoulos, Achilles, additional, Paris, Laura, additional, Browne, Paul, additional, Thieblemont, Catherine, additional, Schaap, Nicolaas, additional, Sierra, Jorge, additional, Yakoub-Agha, Ibrahim, additional, Garderet, Laurent, additional, Styczynski, Jan, additional, Schoemans, Helene, additional, Moiseev, Ivan, additional, Duarte, Rafael F., additional, Peric, Zinaida, additional, Montoto, Silvia, additional, van Biezen, Anja, additional, Mikulska, Malgorzata, additional, Aljurf, Mahmoud, additional, Ruutu, Tapani, additional, Kröger, Nicolaus, additional, Morris, Curly, additional, Koenecke, Christian, additional, Schoenland, Stefan, additional, and Basak, Grzegorz W., additional

Published
2022
Full Text
View/download PDF

13. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study

Author

Gahrton, Gösta, Iacobelli, Simona, Björkstrand, Bo, Hegenbart, Ute, Gruber, Astrid, Greinix, Hildegard, Volin, Liisa, Narni, Franco, Carella, Angelo Michele, Beksac, Meral, Bosi, Alberto, Milone, Giuseppe, Corradini, Paolo, Schönland, Stefan, Friberg, Kristina, van Biezen, Anja, Goldschmidt, Hartmut, de Witte, Theo, Morris, Curly, Niederwieser, Dietger, Garderet, Laurent, and Kröger, Nicolaus

Published
2013
Full Text
View/download PDF

14. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Author

Waszczuk-Gajda, Anna, Penack, Olaf, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Remenyi, Peter, Russell, Nigel, Ljungman, Per, Trneny, Marek, Mayer, Jiri, Iacobelli, Simona, Kobbe, Guido, Scheid, Christof, Apperley, Jane, Touzeau, Cyrille, Lenhoff, Stig, Jantunen, Esa, Anagnostopoulos, Achilles, Paris, Laura, Browne, Paul, Thieblemont, Catherine, Schaap, Nicolaas, Sierra, Jorge, Yakoub-Agha, Ibrahim, Garderet, Laurent, Styczynski, Jan, Schoemans, Helene, Moiseev, Ivan, Duarte, Rafael F., Peric, Zinaida, Montoto, Silvia, van Biezen, Anja, Mikulska, Malgorzata, Aljurf, Mahmoud, Ruutu, Tapani, Kroeger, Nicolaus, Morris, Curly, Koenecke, Christian, Schoenland, Stefan, Basak, Grzegorz W., Waszczuk-Gajda, Anna, Penack, Olaf, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Remenyi, Peter, Russell, Nigel, Ljungman, Per, Trneny, Marek, Mayer, Jiri, Iacobelli, Simona, Kobbe, Guido, Scheid, Christof, Apperley, Jane, Touzeau, Cyrille, Lenhoff, Stig, Jantunen, Esa, Anagnostopoulos, Achilles, Paris, Laura, Browne, Paul, Thieblemont, Catherine, Schaap, Nicolaas, Sierra, Jorge, Yakoub-Agha, Ibrahim, Garderet, Laurent, Styczynski, Jan, Schoemans, Helene, Moiseev, Ivan, Duarte, Rafael F., Peric, Zinaida, Montoto, Silvia, van Biezen, Anja, Mikulska, Malgorzata, Aljurf, Mahmoud, Ruutu, Tapani, Kroeger, Nicolaus, Morris, Curly, Koenecke, Christian, Schoenland, Stefan, and Basak, Grzegorz W.

Abstract

Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent >= 1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0-100 days, 101 days-1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4-108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1-7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3-5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

Published
2022

15. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

Author

Hayden, Patrick J, Iacobelli, Simona, Pérez-Simón, José Antonio, van Biezen, Anja, Minnema, Monique, Niittyvuopio, Riitta, Schönland, Stefan, Meijer, Ellen, Blaise, Didier, Milpied, Noel, Márquez-Malaver, Francisco J, Veelken, Joan Hendrik, Maertens, Johan, Michallet, Mauricette, Cammenga, Jörg, N'Guyen, Stephanie, Niederwieser, Dietger, Hunault-Berger, Mathilde, Henri Bourhis, Jean, Passweg, Jakob, Bermudez, Arancha, Chalandon, Yves, Yakoub-Agha, Ibrahim, Garderet, Laurent, Kröger, Nicolaus, Hayden, Patrick J, Iacobelli, Simona, Pérez-Simón, José Antonio, van Biezen, Anja, Minnema, Monique, Niittyvuopio, Riitta, Schönland, Stefan, Meijer, Ellen, Blaise, Didier, Milpied, Noel, Márquez-Malaver, Francisco J, Veelken, Joan Hendrik, Maertens, Johan, Michallet, Mauricette, Cammenga, Jörg, N'Guyen, Stephanie, Niederwieser, Dietger, Hunault-Berger, Mathilde, Henri Bourhis, Jean, Passweg, Jakob, Bermudez, Arancha, Chalandon, Yves, Yakoub-Agha, Ibrahim, Garderet, Laurent, and Kröger, Nicolaus

Published
2020

16. Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Hayden, Patrick J, Iacobelli, Simona, Pérez-Simón, José Antonio, van Biezen, Anja, Minnema, Monique, Niittyvuopio, Riitta, Schönland, Stefan, Meijer, Ellen, Blaise, Didier, Milpied, Noel, Márquez-Malaver, Francisco J, Veelken, Joan Hendrik, Maertens, Johan, Michallet, Mauricette, Cammenga, Jörg, N'Guyen, Stephanie, Niederwieser, Dietger, Hunault-Berger, Mathilde, Henri Bourhis, Jean, Passweg, Jakob, Bermudez, Arancha, Chalandon, Yves, Yakoub-Agha, Ibrahim, Garderet, Laurent, Kröger, Nicolaus, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Hayden, Patrick J, Iacobelli, Simona, Pérez-Simón, José Antonio, van Biezen, Anja, Minnema, Monique, Niittyvuopio, Riitta, Schönland, Stefan, Meijer, Ellen, Blaise, Didier, Milpied, Noel, Márquez-Malaver, Francisco J, Veelken, Joan Hendrik, Maertens, Johan, Michallet, Mauricette, Cammenga, Jörg, N'Guyen, Stephanie, Niederwieser, Dietger, Hunault-Berger, Mathilde, Henri Bourhis, Jean, Passweg, Jakob, Bermudez, Arancha, Chalandon, Yves, Yakoub-Agha, Ibrahim, Garderet, Laurent, and Kröger, Nicolaus

Published
2020

17. Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP

Author

Hayden, Patrick J., Iacobelli, Simona, Pérez-Simón, José A., van Biezen, Anja, Minnema, Monique, Niittyvuopio, Riitta, Schönland, Stefan, Meijer, Ellen, Blaise, Didier, Milpied, Noel, Márquez-Malaver, Francisco José, Veelken, Joan Hendrik, Maertens, Johan, Michallet, Mauricette, Cammenga, Jörg, N'Guyen, Stephanie, Niederwieser, Dietger, Hunault‐Berger, Mathilde, Bourhis, Jean, Passweg, Jakob, Bermúdez, Arantxa, Chalandon, Yves, Yakoub‐Agha, Ibrahim, Garderet, Laurent, Kroger, Nicolaus, Hayden, Patrick J., Iacobelli, Simona, Pérez-Simón, José A., van Biezen, Anja, Minnema, Monique, Niittyvuopio, Riitta, Schönland, Stefan, Meijer, Ellen, Blaise, Didier, Milpied, Noel, Márquez-Malaver, Francisco José, Veelken, Joan Hendrik, Maertens, Johan, Michallet, Mauricette, Cammenga, Jörg, N'Guyen, Stephanie, Niederwieser, Dietger, Hunault‐Berger, Mathilde, Bourhis, Jean, Passweg, Jakob, Bermúdez, Arantxa, Chalandon, Yves, Yakoub‐Agha, Ibrahim, Garderet, Laurent, and Kroger, Nicolaus

Abstract

[Objectives] The aim of this study was to compare the effect of the intensity of conditioning approaches used in allogeneic transplantation in myeloma—reduced intensity conditioning (RIC), non‐myeloablative (NMA), myeloablative conditioning (MAC) or Auto‐AlloHCT—on outcomes in patients who had had a prior autologous transplant., [Methods] A retrospective analysis of the EBMT database (1991‐2012) was performed., [Results] A total of 344 patients aged between 40 and 60 years at the time of alloHCT were identified: 169 RIC, 69 NMA, 65 MAC and 41 Auto‐Allo transplants. At a median follow‐up of 54 months, the probabilities of overall survival (OS) at 5 years were 39% (95% CI 31%‐47%), 45% (95% CI 32%‐57%), 19% (95% CI 6%‐32%) and 34% (95% CI 17%‐51%), respectively. Status at allogeneic HCT other than CR or PR conferred a 70% higher risk of death and a 40% higher risk of relapse. OS was markedly lower in the MAC group (P = .004). MAC alloHCT was associated with a higher risk of death than RIC alloHCT until 2002 (HR = 4.1, P < .001) but not after 2002 (HR = 1.2, P = .276)., [Conclusion] From 1991 to 2002, MAC was associated with poorer OS. Between 2003 and 2012, there were no significant differences in outcomes based on these different approaches.

Published
2020

18. Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT

Author

Shimoni, Avichai, primary, Robin, Marie, additional, Iacobelli, Simona, additional, van Biezen, Anja, additional, Beelen, Dietrich Wilhelm, additional, Mufti, Ghulam J., additional, Ciceri, Fabio, additional, Kanz, Lothar, additional, Volin, Liisa, additional, Blaise, Didier, additional, Ganser, Arnold, additional, Luft, Thomas, additional, Chevallier, Patrice, additional, Schwerdtfeger, Rainer, additional, de Witte, Theo, additional, Kroger, Nicolaus, additional, Nagler, Arnon, additional, and Yakoub-Agha, Ibrahim, additional

Published
2020
Full Text
View/download PDF

19. Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Pair Analysis of Patients from a Prospective Randomized Trial and the European Blood and Marrow Transplantation Society Registry

Author

Beelen, Dietrich W., primary, Iacobelli, Simona, additional, Koster, Linda, additional, Eikema, Dirk-Jan, additional, van Biezen, Anja, additional, Stoelzel, Friedrich, additional, Ciceri, Fabio, additional, Bethge, Wolfgang, additional, Dreger, Peter, additional, Wagner, Eva-Maria, additional, Reményi, Péter, additional, Stelljes, Matthias, additional, and Markiewicz, Miroslaw, additional

Published
2019
Full Text
View/download PDF

21. A New Method for Estimating Treatment-Related Mortality for Older Patients

Author

de Wreede, Liesbeth C., primary, Schetelig, Johannes, additional, Putter, Hein, additional, van Biezen, Anja, additional, Koster, Linda, additional, Iacobelli, Simona, additional, Perme, Maja Pohar, additional, van Gelder, Michel, additional, Scheid, Christof, additional, Schoenland, Stefan, additional, Hayden, Patrick John, additional, Yakoub-Agha, Ibrahim, additional, Robin, Marie, additional, and Kroeger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

22. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

Author

Guardiola, Philippe, Runde, Volker, Bacigalupo, Andrea, Ruutu, Tapani, Locatelli, Franco, Boogaerts, Marc A., Pagliuca, Antonio, Cornelissen, Jan J., Schouten, Harry C., Carreras, Enric, Finke, Jürgen, van Biezen, Anja, Brand, Ronald, Niederwieser, Dietger, Gluckman, Eliane, and de Witte, Theo M.

Published
2002
Full Text
View/download PDF

23. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant : a retrospective study by the Chronic Malignancies Working Party of EBMT

Author

McLornan, Donal P., Szydlo, Richard, Robin, Marie, van Biezen, Anja, Koster, Linda, Blok, Henrik J. P., Van Lint, Maria T., Finke, Juergen, Vitek, Antonin, Carlson, Kristina, Griskevicius, Laimonas, Holler, Ernst, Itala-Remes, Maija, Schaap, Michel, Socie, Gerard, Bay, Jacques-Olivier, Beguin, Yves, Bruno, Benedetto, Cornelissen, Jan J., Gedde-Dahl, Tobias, Ljungman, Per, Rubio, Marie T., Yakoub-Agha, Ibrahim, Klyuchnikov, Evgeny, Olavarria, Eduardo, Chalandon, Yves, Kroeger, Nicolaus, McLornan, Donal P., Szydlo, Richard, Robin, Marie, van Biezen, Anja, Koster, Linda, Blok, Henrik J. P., Van Lint, Maria T., Finke, Juergen, Vitek, Antonin, Carlson, Kristina, Griskevicius, Laimonas, Holler, Ernst, Itala-Remes, Maija, Schaap, Michel, Socie, Gerard, Bay, Jacques-Olivier, Beguin, Yves, Bruno, Benedetto, Cornelissen, Jan J., Gedde-Dahl, Tobias, Ljungman, Per, Rubio, Marie T., Yakoub-Agha, Ibrahim, Klyuchnikov, Evgeny, Olavarria, Eduardo, Chalandon, Yves, and Kroeger, Nicolaus

Abstract

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

Published
2018
Full Text
View/download PDF

24. Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Garderet, Laurent, Ziagkos, Dimitris, van Biezen, Anja, Iacobelli, Simona, Finke, Jürgen, Maertens, Johan, Volin, Liisa, Ljungman, Per, Chevallier, Patrice, Passweg, Jakob, Schaap, Nicolaas, Beelen, Dietrich, Nagler, Arnon, Blaise, Didier, Poire, Xavier, Yakoub-Agha, Ibrahim, Lenhoff, Stig, Craddock, Charles, Schots, Rik, Rambaldi, Alessandro, Sanz, Jaime, Jindra, Pavel, Mufti, Ghulam J, Robin, Marie, Kröger, Nicolaus, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Garderet, Laurent, Ziagkos, Dimitris, van Biezen, Anja, Iacobelli, Simona, Finke, Jürgen, Maertens, Johan, Volin, Liisa, Ljungman, Per, Chevallier, Patrice, Passweg, Jakob, Schaap, Nicolaas, Beelen, Dietrich, Nagler, Arnon, Blaise, Didier, Poire, Xavier, Yakoub-Agha, Ibrahim, Lenhoff, Stig, Craddock, Charles, Schots, Rik, Rambaldi, Alessandro, Sanz, Jaime, Jindra, Pavel, Mufti, Ghulam J, Robin, Marie, and Kröger, Nicolaus

Abstract

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P < .001), whereas female recipient sex resulted in improved survival (hazard ratio, .61; 95% CI, .41 to .90; P = .01). We conclude that allogeneic HCT can cure a subset of patients with MDS and a del (5q) abnormality.

Published
2018

25. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Schetelig, Johannes, de Wreede, Liesbeth C., Andersen, Niels S., Moreno, Carol, van Gelder, Michel, Vitek, Antonin, Karas, Michal, Michallet, Mauricette, Machaczka, Maciej, Gramatzki, Martin, Beelen, Dietrich, Finke, Jürgen, Delgado, Julio, Volin, Liisa, Passweg, Jakob, Dreger, Peter, Schaap, Nicolaas, Wagner, Eva, Henseler, Anja, van Biezen, Anja, Bornhäuser, Martin, Iacobelli, Simona, Putter, Hein, Schönland, Stefan O., Kröger, Nicolaus, Esteve, Jordi, Ljungman, Per, de Witte, Theo, Stelljes, Matthias, Sierra, Jorge, Socié, Gerard, Ganser, Arnold, Wulf, Gerhard G., Deconinck, Eric, Faber, Edgar, Feguex, Nathalie, Gedde-Dahl, Tobias, Kolbe, Karin, Chalandon, Yves, Krüger, William, Huynh, Anne, Bourhis, Jean Henri, Schouten, Harry, Ribera Santasusana, Josep M., Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and Chalandon, Yves

Subjects
Oncology, Male, Transplantation Conditioning, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Chronic lymphocytic leukemia, Medizin, QUALITY MANAGEMENT-SYSTEM, Kaplan-Meier Estimate, risk factor analysis, GUIDELINES, Biochemistry, allogeneic stem cell transplantation, centre effects, chronic lymphocytic leukaemia, frailties, Transplantation Conditioning / methods, 0302 clinical medicine, Recurrence, Risk Factors, Leukemia, Lymphocytic, Chronic, B-Cell / mortality, Registries, Delivery of Health Care / statistics & numerical data, IBRUTINIB, ddc:616, 0303 health sciences, ALEMTUZUMAB, Hazard ratio, Hematopoietic Stem Cell Transplantation, Professional Practice, Hematology, Middle Aged, 3. Good health, Europe, 030220 oncology & carcinogenesis, ABT-199, Cohort, SURVIVAL, Alemtuzumab, Female, Europe / epidemiology, medicine.drug, Adult, medicine.medical_specialty, Allogeneic transplantation, Immunology, Lower risk, DIAGNOSIS, Settore MED/01 - Statistica Medica, 03 medical and health sciences, Leukemia, Lymphocytic, Chronic, B-Cell / therapy, Hematopoietic Stem Cell Transplantation / methods, Internal medicine, medicine, Humans, Karnofsky Performance Status, 030304 developmental biology, Aged, Retrospective Studies, business.industry, Proportional hazards model, CHRONIC LYMPHOCYTIC-LEUKEMIA, Retrospective cohort study, STEM-CELL TRANSPLANTATION, Cell Biology, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Confidence interval, Surgery, Professional Practice / statistics & numerical data, Transplantation, business, Delivery of Health Care, 030215 immunology, RESPONSES
Abstract

Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Outcomes of interest were Event-Free Survival (EFS) up to 5 years after transplantation and mortality in the first 100 days after alloHCT. Outcomes were analyzed by means of the Kaplan-Meier method and Cox proportional hazards models with a frailty (random effects) component to take into account unexplained center heterogeneity. The following factors describing center characteristics or the transplant procedure were analyzed: experience in alloHCT in general and, for CLL specifically, accreditation by the Joint Accreditation Committee-ISCT & EBMT (JACIE), Gross National Income (GNI)/capita based on purchasing power parity (PPP) (GNI/cap), donor type, donor-patient sex-match, type of conditioning, stem cell source and T-cell depletion (TCD). Results:Five-year EFS of the whole cohort was 37% (95% Confidence Interval, 33%-42%), Day-100 survival was 90% (88%-92%). Experience of the transplant center was measured by the number of all alloHCTs, and alloHCTs for patients with CLL respectively. The median total number of alloHCTs per center per year was 45 (range 0-169) and the median number of CLL alloHCTs was only 2 per center per year (range 0-19). Greater experience with transplantation of patients with CLL (Hazard Ratio (HR) 0.96 per additional transplant, p=0.002), JACIE accreditation (HR 0.7, p=0.045) and a higher GNI/cap (HR 0.4, 95% CI 0.2-0.96, p=0.04) showed a protective impact on 5-year EFS in the Cox model. In vivo TCD with alemtuzumab (HR 1.5 compared to no TCD, p=0.03) and a female donor for a male patient (HR 1.4 compared to a male donor for a male patient, p=0.02) were the only procedure-related factors significantly associated with EFS. Event-Free Survival after in vivo TCD with Anti-Thymocyte-Globulin or after ex vivo TCD was comparable to EFS without TCD (HR 0.9, 0.7-1.3, p=0.6; HR 0.9, 0.5-1.6, p=0.8). Non-myeloablative conditioning did not have a negative impact on 5-year EFS, and exposed patients to a lower risk of non-relapse mortality. Measured and unmeasured center characteristics did not have a significant impact on 100-day mortality. Even when correcting for patient-, procedure- and center-related characteristics, there was still significant variation in center outcome, expressed by center-specific HRs derived from the frailty models, ranging from 0.6 to 1.2. Their impact is illustrated in a model-based plot for EFS (see Figure) which shows outcomes for three reference patients with the same characteristics who would be transplanted in three centers with the same measured characteristics but with the highest, average and lowest HRs in the dataset. These unexplained center effects likely represent a mixture of differences which could apply to the location of the transplant center, unmeasured characteristics of the patient population transplanted at this center, selection criteria which were not reported and factors determining the success of the transplant procedure which might differ between centers. Conclusion: We have confirmed that both center- and procedure-related factors have a significant impact on the EFS of patients with CLL undergoing alloHCT. Our results may help to interpret outcomes of single or multicenter studies better. Since non-myeloablative conditioning did not have a negative impact on EFS and exposed patients to a lower risk of non-relapse mortality, this approach should be favored for future alloHCT for CLL. Probability of Event-Free Survival up to Five Years Post-HCT for three Reference Patients Contribution: J.S. designed the research and wrote the paper. L.C.d.W conducted the statistical analysis and produced the figure. Figure Figure. Disclosures Schetelig: Sanofi: Honoraria. Gramatzki:Janssen: Other: Travel/Accommodation/Expenses, Research Funding. Dreger:Gilead: Consultancy; Gilead: Speakers Bureau; Janssen: Consultancy; Novartis: Speakers Bureau; Novartis: Consultancy; Roche: Consultancy.

Published
2017

26. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT

Author

Gagelmann, Nico, primary, Eikema, Diderik-Jan, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Nahi, Hareth, additional, Stoppa, Anne-Marie, additional, Masszi, Tamás, additional, Caillot, Denis, additional, Lenhoff, Stig, additional, Udvardy, Miklos, additional, Crawley, Charles, additional, Arcese, William, additional, Mariette, Clara, additional, Hunter, Ann, additional, Leleu, Xavier, additional, Schipperus, Martin, additional, Delforge, Michel, additional, Pioltelli, Pietro, additional, Snowden, John A., additional, Itälä-Remes, Maija, additional, Musso, Maurizio, additional, van Biezen, Anja, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2018
Full Text
View/download PDF

27. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

Author

Schmid, Christoph, primary, de Wreede, Liesbeth C., additional, van Biezen, Anja, additional, Finke, Jürgen, additional, Ehninger, Gerhard, additional, Ganser, Arnold, additional, Volin, Liisa, additional, Niederwieser, Dietger, additional, Beelen, Dietrich, additional, Alessandrino, Paolo, additional, Kanz, Lothar, additional, Schleuning, Michael, additional, Passweg, Jakob, additional, Veelken, Hendrik, additional, Maertens, Johan, additional, Cornelissen, Jan J., additional, Blaise, Didier, additional, Gramatzki, Martin, additional, Milpied, Noel, additional, Yakoub-Agha, Ibrahim, additional, Mufti, Ghulam, additional, Rovira, Montserrat, additional, Arnold, Renate, additional, de Witte, Theo, additional, Robin, Marie, additional, and Kröger, Nikolaus, additional

Published
2017
Full Text
View/download PDF

28. Allogeneic Stem Cell Transplantation for Patients Age >= 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT

Author

Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Juergen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yanez, Lucrecia, Beguin, Yves, Sill, Heinz, Scheid, Christof, Stelljes, Matthias, Ganser, Arnold, Zachee, Pierre, Selleslag, Dominik, de Witte, Theo, Robin, Marie, Kroeger, Nicolaus, Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Juergen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yanez, Lucrecia, Beguin, Yves, Sill, Heinz, Scheid, Christof, Stelljes, Matthias, Ganser, Arnold, Zachee, Pierre, Selleslag, Dominik, de Witte, Theo, Robin, Marie, and Kroeger, Nicolaus

Abstract

In this retrospective analysis we evaluated the outcome of 313 patients aged >= 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients >= 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P =.01) and 46% (P =.002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than >= 70 years with MDS. (C) 2017 American Society for Blood and Marrow Transplantation.

Published
2017

29. Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party

Author

Sobh, Mohamad, primary, Michallet, Mauricette, additional, Dubois, Valérie, additional, Iacobelli, Simona, additional, Koster, Linda, additional, Van Biezen, Anja, additional, Fegueux, Nathalie, additional, Tabrizi, Reza, additional, Finke, Jürgen, additional, El-Cheikh, Jean, additional, Schipperus, Martin, additional, Meijer, Ellen, additional, von dem Borne, Peter, additional, Petersen, Eefke, additional, Russell, Nigel, additional, Tholouli, Eleni, additional, Passweg, Jakob, additional, Garban, Frédéric, additional, Maertens, Johan, additional, Chevalier, Patrice, additional, Maillard, Natacha, additional, Volin, Liisa, additional, Francois, Sylvie, additional, Lioure, Bruno, additional, Beguin, Yves, additional, Gluckman, Eliane, additional, Ruggeri, Annalisa, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

30. Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

Author

Sánchez-Ortega, Isabel, primary, Basak, Grzegorz W., additional, Beohou, Eric, additional, van der Werf, Steffie, additional, Labopin, Myriam, additional, van Biezen, Anja, additional, Kroeger, Nicolaus, additional, Montoto, Silvia, additional, Nagler, Arnon, additional, Dreger, Peter, additional, Goldschmidt, Hartmut, additional, Blaise, Didier, additional, Einsele, Hermann, additional, Finke, Jürgen, additional, Russell, Nigel H, additional, Haenel, Mathias, additional, Potter, Michael, additional, Caillot, Denis, additional, Salwender, Hans-Juergen, additional, Ljungman, Per T., additional, Craddock, Charles, additional, Garderet, Laurent, additional, Sureda, Anna, additional, Mohty, Mohamad, additional, Ruutu, Tapani, additional, and Duarte, Rafael F., additional

Published
2016
Full Text
View/download PDF

32. Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Koster, Linda, additional, Dreger, Peter, additional, Johansson, Jan-Erik, additional, Leleu, Xavier, additional, Potter, Michael, additional, Krejci, Marta, additional, Peschel, Christian, additional, Radocha, Jakub, additional, Ganser, Arnold, additional, Metzner, Bernd, additional, Paoli, Nicoli, additional, Schäfer-Eckart, Kerstin, additional, Pohlreich, David, additional, Lenain, Pascal, additional, Grasso, Mariella, additional, Caillot, Denis, additional, Einsele, Hermann, additional, Sengeloev, Henrik, additional, Meuleman, Nathalie, additional, Ciceri, Fabio, additional, Schönland, Stefan, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

33. Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia

Author

Lawless, Sarah, primary, Simona, Iacobelli, additional, van Biezen, Anja, additional, Koster, Linda, additional, Chevallier, Patrice, additional, Blaise, Didier, additional, Foà, Roberto, additional, Tabrizi, Reza, additional, Schaap, Nicolaas PM, additional, Lenhoff, Stig, additional, Russell, Nigel H., additional, Poiré, Xavier, additional, Petersen, Eefke, additional, Cornelissen, Jan J., additional, Di Bartolomeo, Paolo, additional, Wilson, Keith, additional, Schipperus, Martin, additional, Lioure, Bruno, additional, Arcese, William, additional, Mufti, Ghulam J, additional, Snowden, John A, additional, Finke, Jurgen, additional, Morris, Curly, additional, Garderet, Laurent, additional, Kröger, Nicolaus, additional, and Schönland, Stefan, additional

Published
2016
Full Text
View/download PDF

34. Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP)

Author

Kröger, Nicolaus, primary, Putter, Hein, additional, De Wreede, Liesbeth, additional, van Biezen, Anja, additional, Ziagkos, Dimitris, additional, Volin, Liisa, additional, Maertens, Johan, additional, Finke, Jürgen, additional, Ljungman, Per T., additional, Russell, Nigel H., additional, Yakoub-Agha, Ibrahim, additional, Schaap, Michel, additional, Craddock, Charles, additional, Mufti, Ghulam J, additional, Chevallier, Patrice, additional, Passweg, Jakob R, additional, Milpied, Noel, additional, Blaise, Didier, additional, Bourhis, Jean-Henri, additional, Gedde-Dahl, Tobias, additional, Espiga, Carlos Richard, additional, Cornelissen, Jan J., additional, Göhring, Gudrun, additional, Schetelig, Johannes, additional, de Witte, Theo, additional, and Robin, Marie, additional

Published
2016
Full Text
View/download PDF

35. Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Author

van Gelder, Michel, primary, Ziagkos, Dimitris, additional, de Wreede, Liesbeth C, additional, van Biezen, Anja, additional, Dreger, Peter, additional, Gramatzki, Martin, additional, Stelljes, Matthias, additional, Smedegaard Andersen, Niels, additional, Schaap, Nicolaas PM, additional, Vitek, Antonin, additional, Beelen, Dietrich, additional, Volin, Liisa, additional, Finke, Jürgen, additional, Passweg, Jakob R, additional, Ganser, Arnold, additional, Machaczka, Maciej J, additional, Delgado, Julio, additional, Krüger, William, additional, Faber, Edgar, additional, Socie, Gerard, additional, Jindra, Pavel, additional, Afanasyev, Boris V, additional, Theobald, Matthias, additional, Chalandon, Yves, additional, Henseler, Anja, additional, Schoenland, Stefan O., additional, Nicolaus, Kroger, additional, and Schetelig, Johannes, additional

Published
2016
Full Text
View/download PDF

36. Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Schetelig, Johannes, primary, de Wreede, Liesbeth C, additional, Andersen, Niels S., additional, Moreno, Carol, additional, van Gelder, Michel, additional, Vitek, Antonin, additional, Karas, Michal, additional, Michallet, Mauricette, additional, Machaczka, Maciej J, additional, Gramatzki, Martin, additional, Beelen, Dietrich W., additional, Finke, Jurgen, additional, Delgado, Julio, additional, Volin, Liisa, additional, Passweg, Jakob, additional, Dreger, Peter, additional, Schaap, Nicolaas PM, additional, Theobald, Matthias, additional, Henseler, Anja, additional, van Biezen, Anja, additional, Bornhaeuser, Martin, additional, Iacobella, Simona, additional, Putter, Hein, additional, Schönland, Stefen, additional, and Kröger, Nicolaus, additional

Published
2016
Full Text
View/download PDF

37. Outcome of Patients with Second Cancer after Hematopoietic Stem Cell Transplantation: On Behalf of the Complications and Quality of Life Working Party of the EBMT

Author

Tichelli, André, primary, Beohou, Eric, additional, Labopin, Myriam, additional, Socié, Gérard, additional, Rovó, Alicia, additional, Badoglio, Manuela, additional, van Biezen, Anja, additional, Basak, Grzegorz, additional, Duarte, Rafael F., additional, and Salooja, Nina, additional

Published
2016
Full Text
View/download PDF

38. Mother Donors Improve Outcomes after HLA Haploidentical Hematopoietic Transplantation: A Retrospective Study By the Cell Therapy and Immunobiology Working Party of the EBMT

Author

Velardi, Andrea, primary, Ruggeri, Loredana, additional, Ziagkos, Dimitris, additional, van Biezen, Anja, additional, Merluzzi, Mara, additional, Bondanza, Attilio, additional, Bootsman, Nathasja, additional, Massei, Maria Speranza, additional, Amico, Lucia, additional, Piccinelli, Sara, additional, Noviello, Maddalena, additional, Ciceri, Fabio, additional, Klingebiel, Thomas, additional, Koc, Yener, additional, Veelken, Hendrik, additional, Locatelli, Franco, additional, Arcese, William, additional, Gruhn, Bernd, additional, Salvi, Flavia, additional, Bonini, Chiara, additional, and van Rood, Jon J., additional

Published
2016
Full Text
View/download PDF

39. Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT

Author

Kröger, Nicolaus, primary, Eikema, Diderik-Jan, additional, De Wreede, Liesbeth, additional, van Biezen, Anja, additional, Beelen, Dietrich W., additional, Finke, Jürgen, additional, Koenecke, Christian, additional, Niederwieser, Dietger, additional, Bornhäuser, Martin, additional, Schönland, Stefan, additional, Mufti, Ghulam J, additional, Stuhler, Gernot, additional, Maertens, Johan, additional, Theobald, Matthias, additional, Kobbe, Guido, additional, Volin, Liisa, additional, Wulf, Gerald, additional, Kahls, Peter, additional, Milpied, Noel, additional, Greinix, Hildegard, additional, Masszi, Tamás, additional, Nagler, Arnon, additional, Chalandon, Yves, additional, and Robin, Marie, additional

Published
2016
Full Text
View/download PDF

40. Allogeneic Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT

Author

Basak, Grzegorz W., primary, Sánchez-Ortega, Isabel, additional, Beohou, Eric, additional, van der Werf, Steffie, additional, Labopin, Myriam, additional, van Biezen, Anja, additional, Dreger, Peter, additional, Montoto, Silvia, additional, DuFour, Carlo, additional, Kroger, Nicolaus, additional, Nagler, Arnon, additional, Ehninger, Gerhard, additional, Niederwieser, Dietger, additional, Finke, Jurgen, additional, Beelen, Dietrich W., additional, Kanz, Lothar, additional, Tischer, Johanna, additional, Stuhler, Gernot, additional, Mufti, Ghulam J, additional, Glass, Bertram, additional, Arnold, Renate, additional, Sureda, Anna, additional, Mohty, Mohamad, additional, Ruutu, Tapani, additional, and Duarte, Rafael F., additional

Published
2016
Full Text
View/download PDF

41. Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Hussein, Ayad Ahmed, Halkes, Constantijn M., Socié, Gérard, Tichelli, André, von dem Borne, Peter A., Schaap, Michel N.P.M., Foa, Robin, Ganser, Arnold, Dufour, Carlo, Bacigalupo, Andrea, Locasciulli, Anna, Aljurf, Mahmoud, Peters, Christina, Robin, Marie, van Biezen, Anja A., Volin, Liisa, De Witte, Theo, Marsh, Judith, Passweg, Jakob R., and Kröger, Nicolas

Published
2014
Full Text
View/download PDF

42. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

Author

Alchalby, Haefaa, Zabelina, Tatjana, Stübig, Thomas, van Biezen, Anja, Bornhäuser, Martin, Di Bartolomeo, Paolo, Beelen, Dietrich, Cahn, Jean Yves, Dreger, Peter, Schroyens, William, de Witte, Theo, Olavarria, Eduardo, and Kröger, Nicolaus

Published
2014
Full Text
View/download PDF

43. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.

Author

UCL - (SLuc) Service d'hématologie, Gratwohl, Alois, Iacobelli, Simona, Bootsman, Natalia, van Biezen, Anja, Baldomero, Helen, Arcese, William, Arnold, Renate, Bron, Dominique, Cordonnier, Catherine, Ernst, Peter, Ferrant, Augustin, Frassoni, Francesco, Gahrton, Gösta, Richard, Carlos, Kolb, Hans Jochem, Link, Hartmut, Niederwieser, Dietger, Ruutu, Tapani, Schattenberg, Anton, Schmitz, Norbert, Torres-Gomez, Antonio, Zwaan, Ferry, Apperley, Jane, Olavarria, Eduardo, Kröger, Nicolaus, UCL - (SLuc) Service d'hématologie, Gratwohl, Alois, Iacobelli, Simona, Bootsman, Natalia, van Biezen, Anja, Baldomero, Helen, Arcese, William, Arnold, Renate, Bron, Dominique, Cordonnier, Catherine, Ernst, Peter, Ferrant, Augustin, Frassoni, Francesco, Gahrton, Gösta, Richard, Carlos, Kolb, Hans Jochem, Link, Hartmut, Niederwieser, Dietger, Ruutu, Tapani, Schattenberg, Anton, Schmitz, Norbert, Torres-Gomez, Antonio, Zwaan, Ferry, Apperley, Jane, Olavarria, Eduardo, and Kröger, Nicolaus

Abstract

In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated. Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0-52.4 % vs 52.9 %, 43.2-62.6 %; p = 0.355, log rank test). Additional splenic irradiation failed to reduce relapse incidence. It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Society for Blood and Marrow Transplantation (EBMT) risk sore. This needs to be considered today when treatment options are discussed for patients who failed initial tyrosine kinase inhibitor therapy and have an available low risk HLA-identical donor.

Published
2016

44. Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study

Author

Gratwohl, Alois, Ernst, Peter, Ferrant, Augustin, Frassoni, Francesco, Gahrton, Gosta, Richard, Carlos, Kolb, Hans Jochem, Link, Hartmut, Niederwieser, Dietger, Ruutu, Tapani, Schattenberg, Anton, Iacobelli, Simona, Schmitz, Norbert, Torres-Gomez, Antonio, Zwaan, Ferry F.E., Apperley, Jane J.F., Olavarria, Eduardo, Kröger, Nicolaus, Bootsman, Natalia, van Biezen, Anja, Baldomero, Helen, Arcese, William, Arnold, Renate, Bron, Dominique, Cordonnier, Catherine, Gratwohl, Alois, Ernst, Peter, Ferrant, Augustin, Frassoni, Francesco, Gahrton, Gosta, Richard, Carlos, Kolb, Hans Jochem, Link, Hartmut, Niederwieser, Dietger, Ruutu, Tapani, Schattenberg, Anton, Iacobelli, Simona, Schmitz, Norbert, Torres-Gomez, Antonio, Zwaan, Ferry F.E., Apperley, Jane J.F., Olavarria, Eduardo, Kröger, Nicolaus, Bootsman, Natalia, van Biezen, Anja, Baldomero, Helen, Arcese, William, Arnold, Renate, Bron, Dominique, and Cordonnier, Catherine

Abstract

In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML). Between 1986 and 1989, a total of 229 patients with CML were randomized; of these, 225 (98 %; 112 with, 113 without splenic irradiation) could be identified in the database and their survival updated. Results confirmed the early findings with no significant differences in all measured endpoints (overall survival at 25 years: 42.7 %, 32.0–52.4 % vs 52.9 %, 43.2–62.6 %; p = 0.355, log rank test). Additional splenic irradiation failed to reduce relapse incidence. It did not increase non-relapse mortality nor the risk of late secondary malignancies. Comforting are the long-term results from this predefined consecutive cohort of patients: more than 60 % were alive at plus 25 years when they were transplanted with a low European Society for Blood and Marrow Transplantation (EBMT) risk sore. This needs to be considered today when treatment options are discussed for patients who failed initial tyrosine kinase inhibitor therapy and have an available low risk HLA-identical donor., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2016

45. Use of the quality management system 'JACIE' and outcome after hematopoietic stem cell transplantation

Author

Gratwohl, Alois, Brand, Roland, McGrath, Eoin, van Biezen, Anja, Sureda, Anna, Ljungman, Per, Baldomero, Helen, Chabannon, Christian, Apperley, Jane, Joint Accreditation Committee (JACIE), International Society for Cellular Therapy, European Group for Blood and Marrow Transplantatio, and European Leukemia Net

Subjects
Male, Quality Control, medicine.medical_specialty, Outcome assessment (Medical care), Quality Assurance, Health Care, medicine.medical_treatment, Improved survival, Hematopoietic stem cell transplantation, Stem cells, Accreditation, Recurrence, Risk Factors, Outcome Assessment, Health Care, medicine, Overall survival, Humans, Mortality, Intensive care medicine, Retrospective Studies, Patient Care Team, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Articles, Garantia de qualitat, Quality assurance, Transplantation, Quality management system, Cohort, Emergency medicine, Avaluació de resultats (Assistència mèdica), Female, business, Cèl·lules mare, Total Quality Management
Abstract

Competent authorities, healthcare payers and hospitals devote increasing resources to quality management systems but scientific analyses searching for an impact of these systems on clinical outcome remain scarce. Earlier data indicated a stepwise improvement in outcome after allogeneic hematopoietic stem cell transplantation with each phase of the accreditation process for the quality management system “JACIE”. We therefore tested the hypothesis that working towards and achieving “JACIE” accreditation would accelerate improvement in outcome over calendar time. Overall mortality of the entire cohort of 107,904 patients who had a transplant (41,623 allogeneic, 39%; 66,281 autologous, 61%) between 1999 and 2006 decreased over the 14-year observation period by a factor of 0.63 per 10 years (hazard ratio: 0.63; 0.58–0.69). Considering “JACIE“-accredited centers as those with programs having achieved accreditation by November 2012, at the latest, this improvement was significantly faster in “JACIE”-accredited centers than in non-accredited centers (approximately 5.3% per year for 49,459 patients versus approximately 3.5% per year for 58,445 patients, respectively; hazard ratio: 0.83; 0.71–0.97). As a result, relapse-free survival (hazard ratio 0.85; 0.75–0.95) and overall survival (hazard ratio 0.86; 0.76–0.98) were significantly higher at 72 months for those patients transplanted in the 162 “JACIE“-accredited centers. No significant effects were observed after autologous transplants (hazard ratio 1.06; 0.99–1.13). Hence, working towards implementation of a quality management system triggers a dynamic process associated with a steeper reduction in mortality over the years and a significantly improved survival after allogeneic stem cell transplantation. Our data support the use of a quality management system for complex medical procedures.

Published
2014

46. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation

Author

Cook, Gordon, primary, Iacobelli, Simona, additional, van Biezen, Anja, additional, Ziagkos, Dimitris, additional, LeBlond, Veronique, additional, Abraham, Julie, additional, McQuaker, Grant, additional, Schoenland, Stefan, additional, Rambaldi, Alessandro, additional, Halaburda, Kazimierz, additional, Rovira, Maria, additional, Sica, Simona, additional, Byrne, Jenny, additional, Sanz, Ramon Garcia, additional, Nagler, Arnon, additional, van de Donk, Niels W.C.J., additional, Sinisalo, Marjatta, additional, Cook, Mark, additional, Kröger, Nicolaus, additional, De Witte, Theo, additional, Morris, Curly, additional, and Garderet, Laurant, additional

Published
2016
Full Text
View/download PDF

47. Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

Author

UCL - (SLuc) Service d'hématologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Sahebi, Firoozeh, Iacobelli, Simona, Van Biezen, Anja, Volin, Liisa, Dreger, Peter, Michallet, Mauricette, Ljungman, Per T., De Witte, Theo, Henseler, Anja, Schaap, Nicolaas P.M., López-Corral, Lucía, Poire, Xavier, Passweg, Jakob, Hamljadi, Rose-Marie, Thomas, Sandra H., Schonland, Stefan, Gahrton, Gösta, Morris, Curly, Kröger, Nicolaus, Garderet, Laurent, UCL - (SLuc) Service d'hématologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, Sahebi, Firoozeh, Iacobelli, Simona, Van Biezen, Anja, Volin, Liisa, Dreger, Peter, Michallet, Mauricette, Ljungman, Per T., De Witte, Theo, Henseler, Anja, Schaap, Nicolaas P.M., López-Corral, Lucía, Poire, Xavier, Passweg, Jakob, Hamljadi, Rose-Marie, Thomas, Sandra H., Schonland, Stefan, Gahrton, Gösta, Morris, Curly, Kröger, Nicolaus, and Garderet, Laurent

Abstract

We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.

Published
2015

48. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes

Author

University of Helsinki, Department of Medicine, Koenecke, Christian, Goehring, Gudrun, de Wreede, Liesbeth C., van Biezen, Anja, Scheid, Christof, Volin, Liisa, Maertens, Johan, Finke, Juergen, Schaap, Nicolaas, Robin, Marie, Passweg, Jakob, Cornelissen, Jan, Beelen, Dietrich, Heuser, Michael, de Witte, Theo, Kroeger, Nicolaus, MDS Subcomm Chronic Malignancies, University of Helsinki, Department of Medicine, Koenecke, Christian, Goehring, Gudrun, de Wreede, Liesbeth C., van Biezen, Anja, Scheid, Christof, Volin, Liisa, Maertens, Johan, Finke, Juergen, Schaap, Nicolaas, Robin, Marie, Passweg, Jakob, Cornelissen, Jan, Beelen, Dietrich, Heuser, Michael, de Witte, Theo, Kroeger, Nicolaus, and MDS Subcomm Chronic Malignancies

Abstract

The aim of this study was to determine the impact of the revised 5-group International Prognostic Scoring System cytogenetic classification on outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for Blood and Marrow Transplantation database. A total of 903 patients had sufficient cytogenetic information available at stem cell transplantation to be classified according to the 5-group classification. Poor and very poor risk according to this classification was an independent predictor of shorter relapse-free survival (hazard ratio 1.40 and 2.14), overall survival (hazard ratio 1.38 and 2.14), and significantly higher cumulative incidence of relapse (hazard ratio 1.64 and 2.76), compared to patients with very good, good or intermediate risk. When comparing the predictive performance of a series of Cox models both for relapse-free survival and for overall survival, a model with simplified 5-group cytogenetics (merging very good, good and intermediate cytogenetics) performed best. Furthermore, monosomal karyotype is an additional negative predictor for outcome within patients of the poor, but not the very poor risk group of the 5-group classification. The revised International Prognostic Scoring System cytogenetic classification allows patients with myelodysplastic syndromes to be separated into three groups with clearly different outcomes after stem cell transplantation. Poor and very poor risk cytogenetics were strong predictors of poor patient outcome. The new cytogenetic classification added value to prediction of patient outcome compared to prediction models using only traditional risk factors or the 3-group International Prognostic Scoring System cytogenetic classification.

Published
2015

49. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation

Author

Koenecke, Christian, Goehring, Gudrun, de Wreede, Liesbeth C., van Biezen, Anja, Scheid, Christof, Volin, Liisa, Maertens, Johan, Finke, Juergen, Schaap, Nicolaas, Robin, Marie, Passweg, Jakob, Cornelissen, Jan, Beelen, Dietrich, Heuser, Michael, de Witte, Theo, Kroeger, Nicolaus, Koenecke, Christian, Goehring, Gudrun, de Wreede, Liesbeth C., van Biezen, Anja, Scheid, Christof, Volin, Liisa, Maertens, Johan, Finke, Juergen, Schaap, Nicolaas, Robin, Marie, Passweg, Jakob, Cornelissen, Jan, Beelen, Dietrich, Heuser, Michael, de Witte, Theo, and Kroeger, Nicolaus

Abstract

The aim of this study was to determine the impact of the revised 5-group International Prognostic Scoring System cytogenetic classification on outcome after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for Blood and Marrow Transplantation database. A total of 903 patients had sufficient cytogenetic information available at stem cell transplantation to be classified according to the 5-group classification. Poor and very poor risk according to this classification was an independent predictor of shorter relapse-free survival (hazard ratio 1.40 and 2.14), overall survival (hazard ratio 1.38 and 2.14), and significantly higher cumulative incidence of relapse (hazard ratio 1.64 and 2.76), compared to patients with very good, good or intermediate risk. When comparing the predictive performance of a series of Cox models both for relapse-free survival and for overall survival, a model with simplified 5-group cytogenetics (merging very good, good and intermediate cytogenetics) performed best. Furthermore, monosomal karyotype is an additional negative predictor for outcome within patients of the poor, but not the very poor risk group of the 5-group classification. The revised International Prognostic Scoring System cytogenetic classification allows patients with myelodysplastic syndromes to be separated into three groups with clearly different outcomes after stem cell transplantation. Poor and very poor risk cytogenetics were strong predictors of poor patient outcome. The new cytogenetic classification added value to prediction of patient outcome compared to prediction models using only traditional risk factors or the 3-group International Prognostic Scoring System cytogenetic classification.

Published
2015

50. Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation

Author

Haematologie, Child Health, Regenerative Medicine and Stem Cells, Fioredda, Francesca, Iacobelli, Simona, van Biezen, Anja, Gaspar, Bobby, Ancliff, Phil, Donadieu, Jean, Aljurf, Mahmoud, Peters, Christina, Calvillo, Michaela, Matthes-Martin, Susanne, Morreale, Giuseppe, van 't Veer-Tazelaar, Nelleke, de Wreede, Liesbeth, Al Seraihy, Amal, Yesilipek, Akif, Fischer, Alain, Bierings, Marc, Ozturk, Gulyuz, Smith, Owen, Veys, Paul, Ljungman, Per, Peffault de Latour, Régis, Sánchez de Toledo Codina, José, Or, Reuven, Ganser, Arnold, Afanasyev, Boris, Wynn, Robert, Kalwak, Krzysztof, Marsh, Judith, Dufour, Carlo, Severe Aplastic Anemia the Inborn Error, and the Pediatric Disease Working Parties of the European Society for Blood and Bone Marrow Transplantation (EBMT) and Stem Cell Transplant for Immunodeficiencies in Europe (SCETIDE), Haematologie, Child Health, Regenerative Medicine and Stem Cells, Fioredda, Francesca, Iacobelli, Simona, van Biezen, Anja, Gaspar, Bobby, Ancliff, Phil, Donadieu, Jean, Aljurf, Mahmoud, Peters, Christina, Calvillo, Michaela, Matthes-Martin, Susanne, Morreale, Giuseppe, van 't Veer-Tazelaar, Nelleke, de Wreede, Liesbeth, Al Seraihy, Amal, Yesilipek, Akif, Fischer, Alain, Bierings, Marc, Ozturk, Gulyuz, Smith, Owen, Veys, Paul, Ljungman, Per, Peffault de Latour, Régis, Sánchez de Toledo Codina, José, Or, Reuven, Ganser, Arnold, Afanasyev, Boris, Wynn, Robert, Kalwak, Krzysztof, Marsh, Judith, Dufour, Carlo, and Severe Aplastic Anemia the Inborn Error, and the Pediatric Disease Working Parties of the European Society for Blood and Bone Marrow Transplantation (EBMT) and Stem Cell Transplant for Immunodeficiencies in Europe (SCETIDE)

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results